Navigation Links
Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax

treatments began 24 hours after exposure to B. anthracis spores. Survival rates at 30 days post- exposure were as follows: 90 percent survival with CIP and 100 percent survival with ORI treatment at doses equal to or greater than 3 mg/kg intraperitoneally (multiple dose) or 50 mg/kg intravenously (single dose).

A follow-up experiment showed that ORI or CIP provided significant survival rates even when the start of treatment was delayed to either 36 or 48 hours post-exposure to spores (i.e., until symptoms had begun to appear). In this experiment, ORI was administered at 10 mg/kg once every 2 days while CIP was administered at 30 mg/kg twice daily. Treatments were provided intraperitoneally for 14 days and survivorship was measured at 30 days.

In addition, a single 50 mg/kg intravenous dose of ORI administered 24 hours prior to anthrax exposure provided a 100 percent survival rate at 30 days.

Researchers at USAMRIID and Targanta concluded that their results provide impetus for investigation of whether ORI could serve as an effective therapy for anthrax exposure, requiring fewer doses compared to CIP, or perhaps even as a potential prophylactic agent.

B. anthracis, a bacterium that forms spores and causes anthrax, has been recognized for more than 60 years as a potential biological warfare agent. Such was the case in 2001, when B. anthracis spores were distributed through the U.S. Postal Service, causing 22 cases of anthrax, including five deaths. If treated promptly B. anthracis usually responds effectively to several antibiotics including penicillin, doxycycline and fluoroquinolones (including ciprofloxacin). Though ciprofloxacin is the current standard of treatment for exposure, anthrax has the possibility of being engineered to be multi-drug resistant, which would complicate treatment. The World Health Organization estimates that 50 kg of B. anthracis spores effectively released in a population of 500,000 people would result in 95,000
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ) today ... quarter of 2013 on Monday, February 3, 2014. A press ... close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... the operating highlights and financial results for the fourth quarter ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... May 26 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) ... make a presentation regarding the business strategy of the Company at the Noble ... 1:00 p.m. EDT .  The conference will be held at the Hard Rock ... , , ...
... Inteplast Group,s Integrated Bagging Systems (IBS) Unit is ... packaging division from Uniflex Holdings, part of S. Walter Packaging ... and other medical packaging, and is a valued addition to ... name, sales and customer base into the Inteplast fold. , ...
Cached Medicine Technology:Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010 2Inteplast Acquires Medical Packaging Division 2
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... YORK, NY (April 16, 2014) The cause of ... a new study proposes that neurons may be mistaken ... immune system, similar to the way autoimmune diseases like ... the body,s cells. The study was published April 16, ... a new, and likely controversial, idea in Parkinson,s disease; ...
(Date:4/17/2014)... (BUSM) have discovered that the anti-seizure drug ezogabine, ... findings, reported in the American Journal of ... more effective treatments for alcoholism. , Excessive consumption ... of illness and death in the U.S. and ... productivity of workers and necessitating huge health care ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... media and others interested in the chemical sciences are ... American Chemical Society (ACS) Webinars, focusing on how to ... programs. Scheduled for Thursday, Sept. 16, from 2 ... feature Josephine Yuen, Ph.D., NSF Program Director, speaking on ...
... for Personalized Medicine , Author: Shara Yurkiewicz, Summary: Ten ... the human genome, major changes have made their way ... Title: Personalized Medicine,s Ragged Edge, Author: Leonard M. Fleck, ... spin. But little attention has been given to some ...
... , THURSDAY, Sept. 9 (HealthDay News) -- A ... heads-up about the kinds of medical problems that may face ... to use a computational method to create a score based ... rate during the first three hours after birth. In a ...
... living in California, Laotian/Hmong-Americans have the lowest survival rates ... new study by researchers with the UC Davis School ... largest population-based examination of liver cancer rates among Asian-Americans, ... to detect and treat the disease earlier among Laotian/Hmong-Americans, ...
... Academy of Orthopaedic Surgeons (AAOS) recently approved and released ... periprosthetic joint infections of the hip and knee. Clinical ... ensure that patients receive high quality care. A ... organisms enter the wound during or at any point ...
... By Steven Reinberg HealthDay Reporter , ... their ability to lower cholesterol and prevent heart attacks ... rheumatoid arthritis, Israeli researchers report. "We ... were less likely to develop rheumatoid arthritis over a ...
Cached Medicine News:Health News:American Chemical Society Webinar focuses on NSF's small business funding programs 2Health News:The Hastings Center Report table of contents for September-October 2010 2Health News:The Hastings Center Report table of contents for September-October 2010 3Health News:New Tool Aims to Predict Problems in Preemies 2Health News:UC Davis study finds low liver cancer survival rates among Laotian/Hmong-Americans 2Health News:UC Davis study finds low liver cancer survival rates among Laotian/Hmong-Americans 3Health News:Joint replacement: Does this look infected to you? 2Health News:Joint replacement: Does this look infected to you? 3Health News:Statins May Guard Against Rheumatoid Arthritis 2Health News:Statins May Guard Against Rheumatoid Arthritis 3
... Handbook on Injectable Drugs is a ... it quick and easy to check ... you enter the selected drugs, clear ... so you can quickly take clinical ...
Providing patients and their advocates with a variety of information services and educational materials on clinical research....
... DrDrugs®: Drug Guide for ... over 760 Integrated Calculators ... comprehensive, up-to-date and practical ... in drug dosing calculation ...
Clinician's Pocket Drug Reference 2005 includes key elements of commonly used medications that are essential information for both the student and practicing physician....
Medicine Products: